Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at night. Something else affects those millions of allergy sufferers, according to a new survey: big misconceptions about allergies that may keep people from getting needed relief.
To help put those misconceptions about allergies to rest, Sanofi is teaming up with science educator and television personality Adam Savage, along with allergist Dr. Neeta Ogden, to dispel them with credible information. The goal: help the 50 million allergy sufferers in America get the facts they need to understand and treat their allergies and take back control of their lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8255452-sanofi-allergy-misconceptions-facts-adam-savage/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today congratulated trusted Edwards partner Dr. Albert Starr on receiving the 2015 Institut de France’s Grand Prix Scientifique in a Paris awards ceremony.
The Grand Prix is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. The Institut’s board awarded Starr the Grand Prix in recognition of research that led to the world’s first successful artificial mitral valve implant in 1960. In the last 55 years, millions of patients around the world have benefitted from the emergence of the field of heart valve replacement and the many technological advances that followed.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7536851-france-grand-prix-starr-edwards/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
5 Reasons To Buy An Electric Car. Driving the 2016 Nissan Leaf, I discuss the many benefits of driving an electric vehicle. The instant torque and peak torque from 0 RPM, the incredibly low maintenance (tire rotations and cabin filter changes), the incredible efficiency (about 3x the efficiency of an ICE vehicle), the convenience of charging, and the affordability of leasing an electric car.
Related Videos
Nissan Leaf Review - https://youtu.be/KovdnzywQbs
Free Car? - https://youtu.be/NCdLFhUmubc
References:
Tribology International Study - http://www.sciencedirect.com/science/article/pii/S0301679X11003501
Fuel Economy Study - https://www.fueleconomy.gov/feg/evtech.shtml
SAIC, Inc. (NYSE: SAI) today held an Investor Day event in New York City in which the senior leadership team of the planned spin-off company, Science Applications International Corp. (SAIC), presented its business plans and financial objectives.
SAIC, Inc. previously announced plans to create two independent, publicly traded companies. Upon completion of the planned spin-off transaction, the technical, engineering and enterprise IT services business will retain the name SAIC and trade under (NYSE: SAIC), while the government and commercial solutions company will be named Leidos and trade under (NYSE: LDOS).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63326-saic-presents-planned-company-s-business-financial-objectives-investor-day
The National Inventors Hall of Fame®, in partnership with the United States Patent and Trademark Office (USPTO), will host the Greatest Celebration of American Innovation on May 3-4 in our Nation’s Capital. Events will recognize and celebrate 15 pioneers who have significantly contributed to society through their scientific breakthroughs and patented innovations, culminating in a formal Induction Ceremony on May 4.
This year’s class of Inductees includes innovators such as Iver Anderson (Lead-Free Solder), Marshall Jones (Industrial Lasers), Frances Ligler (Portable Optical Biosensors), and Howard Head (Laminate Ski; Oversized Tennis Racket), just to name a few. To view the full list of 2017 Inductees, visit: http://prn.to/2lgdW84.
To view the multimedia release go to:
https://www.multivu.com/players/English/8040951-national-inventors-hall-of-fame-2017/
Bestselling author Catherynne M. Valente (The Girl Who Circumnavigated Fairyland in a Ship of Her Own Making etc) returns to adult fiction with an eagerly awaited new novel: RADIANCE. She applies the phenomenal talent that made the Fairyland series so popular to give readers what she describes as a decopunk pulp science fiction alt-history space opera mystery set in a Hollywood—and solar system—very different from our own. http://www.catherynnemvalente.com YA, Fantasy, SciFi
Learning science company McGraw-Hill Education today announced the launch of Redbird Language Arts & Writing, a new enhanced personalized learning program that helps students master language arts concepts and build strong foundational writing skills. The new program accomplishes this by combining innovative writing analysis technology, interactive practice and personalized learning. The supplemental curriculum, for grades 2-7 and at-risk secondary students, is available to U.S. schools nationwide.
Originally developed by Stanford University, Redbird’s adaptive learning technology provides a personalized learning experience for each student. Redbird Language Arts & Writing delivers immediate feedback and charts an optimized path through the program based on each individual student’s skillset and level of progress – while also empowering educators with real-time, data-driven insights about their students’ learning.
To view the multimedia release go to:
https://www.multivu.com/players/English/7782356-mcgraw-hill-education-redbird/
Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement.
The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
A Princess of Roumania fantasy, with an extraordinary, intense, compressed SF novel in three parts, each set in its own alternate-history universe. The sections are all rooted in Virginia and the Battle of the Crater, and are also grounded in the real history of the Park family, from differing points of view.
The first section is set in the aftermath of the Civil War, in a world in which the Queen of the North has negotiated a two-nation settlement. The second, taking place in northwestern Massachusetts, investigates a secret project during World War II, in a time somewhat like the present. The third is set in the near-future United States, with aliens from history.
The cumulative effect is awesome. There hasn’t been a three part novel this ambitious in science fiction since Gene Wolfe’s classic The Fifth Head of Cerberus. Find out more at http://us.macmillan.com/allthosevanishedengines/PaulPark Fantasy/Scifi
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer.
Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
